1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


Delayed London Stock Exchange  -  11:39 2022-06-24 am EDT
10788.00 GBX   +3.93%
06/24AstraZeneca-Merck & Co's Lynparza Receives EU Panel's Positive Opinion for New Indication
06/24Sanofi, GSK variant-specific COVID shot found effective against Omicron
06/23AstraZeneca Says Health Canada Expands Approved of Breast Cancer Treatment Enhertu
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Travel, energy stocks drag UK shares lower, weighed by coronavirus fears

10/26/2020 | 05:26am EDT

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)

* Surge in coronavirus cases dents mood

* EU negotiator Barnier extends London visit for Brexit talks

* AstraZeneca gains on positive COVID-19 vaccine update

* Coca-Cola European Partners rise on buyout offer

* FTSE 100 down 1.2%, FTSE 250 drops 1.4%

Oct 26 (Reuters) - London stocks closed sharply lower on Monday, weighed by travel and energy stocks, while a resurgence in novel coronavirus cases stoked fears of a faltering economic recovery and dragged down European markets. After rising nearly 0.1% in morning trade, the blue-chip FTSE 100 index fell 1.2%, led by declines in travel and leisure, personal goods makers, retailers and aero stocks.

Energy and mining weighed the most on the index due to weaker commodity prices.

The domestically focussed mid-cap FTSE 250 index lost 1.4% even as European Union chief negotiator Michel Barnier and his team extended their London visit until Wednesday to try and clinch a Brexit trade deal.

European markets were weighed down by a plunge in tech major SAP, an impasse over the U.S. stimulus package and fears that a resurgence in coronavirus cases could hamper a global economic recovery as governments tighten restrictions on businesses and social activity.

"The fact that (more) countries are now reining in the freedom of people to move around is going to have a detrimental impact on the actual overall activity level in the economy", said Saxo Bank chief investment officer Steen Jakobsen.

"UK is even more challenged due to the COVID-19 close-down and Brexit."

After a stimulus-backed rally from pandemic lows, the FTSE 100 has been trading in tight ranges since June due to Brexit-related uncertainty and concerns over coronavirus curbs.

In a bright spot, AstraZeneca Plc rose 1.7% after the drugmaker resumed the U.S. trial of its experimental COVID-19 vaccine that is being developed with the University of Oxford, and said it produced a similar immune response in both older and younger adults.

The wider healthcare index added 1%.

Educational publisher Pearson Plc added 3% after UBS upgraded the stock to a "buy" rating.

Coca-Cola European Partners (CCEP) rose 0.3% after the soft drink bottler made a buyout offer of $6.6 billion for its Australian peer Coca-Cola Amatil Ltd. (Reporting by Devik Jain in Bengaluru; editing by Aditya Soni and Bernadette Baum)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 3.93% 10788 Delayed Quote.24.31%
EURO / BRITISH POUND (EUR/GBP) -0.05% 0.85992 Delayed Quote.2.11%
FTSE 100 2.68% 7208.81 Delayed Quote.-2.38%
FTSE MID 250 INDEX 2.30% 19123.71 Delayed Quote.-18.56%
MSCI UNITED KINGDOM (STRD) 2.83% 1065.45 Real-time Quote.-11.79%
PEARSON PLC 1.64% 780.8 Delayed Quote.27.33%
S&P UNITED KINGDOM (PDS) 2.70% 1474.53 Real-time Quote.-0.20%
SAP SE 3.30% 92.33 Delayed Quote.-26.08%
All news about ASTRAZENECA PLC
06/24AstraZeneca-Merck & Co's Lynparza Receives EU Panel's Positive Opinion for New Indicati..
06/24Sanofi, GSK variant-specific COVID shot found effective against Omicron
06/23AstraZeneca Says Health Canada Expands Approved of Breast Cancer Treatment Enhertu
06/23EU watchdog backs Valneva's COVID shot as contract talks go on
06/23AstraZeneca Drug Candidate to Treat Wilson Disease Meets Primary Endpoint in Phase 3 Tr..
06/23AstraZeneca's Investigational Drug Meets Primary Endpoint for Wilson Disease
06/23ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Pot..
06/23ASTRAZENECA : ALXN1840 shows rapid and sustained improvement in copper mobilisation from t..
06/22ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively
06/22European Medicines Agency Validates AstraZeneca-Daiichi Sankyo Application for Breast C..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 698 M - -
Net income 2022 4 956 M - -
Net Debt 2022 24 403 M - -
P/E ratio 2022 40,8x
Yield 2022 2,23%
Capitalization 205 B 205 B -
EV / Sales 2022 5,25x
EV / Sales 2023 4,83x
Nbr of Employees 83 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 26
Last Close Price 132,44 $
Average target price 142,15 $
Spread / Average Target 7,33%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC24.31%205 217
JOHNSON & JOHNSON5.02%479 678
PFIZER, INC.-15.17%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202